We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Horizon Discovery Group Selected as Core Facility by Tri-Institutional Therapeutics Discovery Institute
News

Horizon Discovery Group Selected as Core Facility by Tri-Institutional Therapeutics Discovery Institute

Horizon Discovery Group Selected as Core Facility by Tri-Institutional Therapeutics Discovery Institute
News

Horizon Discovery Group Selected as Core Facility by Tri-Institutional Therapeutics Discovery Institute

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Horizon Discovery Group Selected as Core Facility by Tri-Institutional Therapeutics Discovery Institute"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Horizon Discovery Group plc has been selected to act as a core facility by the Tri-Institutional Therapeutics Discovery Institute (TDI). As a core facility, Horizon will provide single and combination drug profiling followed by confirmatory secondary assay services to TDI through its discovery research services unit.

Under the agreement, Horizon will receive up to $500,000 for work to be performed during 2015 and 2016, with the option for additional collaboration work orders thereafter.

Horizon will utilize its unique cHTS (combination High Throughput Screening) platform and Chalice™ analytics software to screen and analyze potentially thousands of small-molecule drugs, therapeutic antibodies or proteins in combination to identify synergistic or antagonistic interactions.  Horizon will also provide a range of optimized cellular assays as follow-ups to identify drug target activity. The first programs are forecast to start in the second half of 2015.

Dr. Darrin M. Disley, Chief Executive Officer of Horizon Discovery Group plc, commented: “Horizon is thrilled to have been chosen as a core facility to support TDI research programs via application of our innovative drug combination screening platform and assay services. The partnership, which provides access to multiple components of our technology platforms and capabilities, reinforces the value that we can provide our customers from ‘sequence to treatment’. We look forward to working with the TDI team and potentially broadening our relationship further in 2016 and 2017.”

Dr. Michael Foley, Sanders Director, TDI, said: “The Tri-Institutional Therapeutics Discovery Institute links researchers in basic and clinical science with experts in drug discovery from the biotech and pharmaceutical industries, with the goal of more efficiently translating discoveries into therapies for disease. We are delighted to be partnering with Horizon Discovery Group and look forward to initiating the programs.”

Advertisement